<DOC>
	<DOCNO>NCT02231853</DOCNO>
	<brief_summary>Allogeneic hematopoetic stem cell transplantation ( SCT ) frequently complicate life threaten viral reactivation . Conventional antiviral therapy suboptimal cytomegalovirus ( CMV ) , adenovirus ( AdV ) Epstein-Barr virus ( EBV ) nonexistent BK virus ( BKV ) . An alternative approach prevent viral reactivation infuse virus-specific cytotoxic T cell ( CTL ) prepare donor early SCT . Such multivirus-specific CTL cell ( MVST ) successfully use number center prevent treat CMV , Ad EBV . Activity BKV-reactive cell study . Multi virus-specific T cell ( MVST ) donor lymphocytes highly enriched viral antigen expand vitro infusion transplant recipient . Viral reactivation particular problem inT cell deplete SCT . Median time CMV reactivation estimate 28 day post T-depleted transplant , infusion MVST within immediate post-SCT period previously study . This protocol first plan series cellular therapy layer exist T lymphocyte deplete transplant platform protocol 13-H-0144 . The aim study determine safety efficacy early infusion MVST direct four common virus cause complication T-depleted SCT . GMP-grade allogeneic MVST stem cell donor generate use monocyte-derived donor dendritic cell ( DCs ) pulse overlap peptide library immunodominant antigen CMV , EBV , Ad , BKV expand IL-7 IL-15 follow IL-2 10-14 day . A fraction routine donor leukapheresis lymphocyte obtain prior stem cell mobilization use generate MVST cell . MVST pass release criterion cryopreserved ready infusion post SCT . Eligible subject NHLBI protocol 13-H-0144 receive single early infusion MVST within 30 day ( target day +14 , range 0-30 day ) post SCT . Phase I safety monitor continue 6 week . Viral reactivation ( CMV , EBV , Ad , BK ) monitor PCR serial blood sampling . The antiviral prophylaxis give acyclovir prevent herpes simplex varicella zoster reactivation . Subjects rise PCR exceed threshold treatment , clinically overt viral disease receive conventional antiviral treatment . Patients develop acute GVHD receive standard treatment systemic steroid . These patient eligible reinfusion MVST steroid taper . The clinical trial design single institution , open label , non-randomized Phase I/II trial MVST transplant recipient , design 3-cohort dose escalation Phase I follow 20 subject extension Phase II maximum tolerate dose cell . Safety monitor continuously period 6 week post T cell transfer . The primary safety endpoint occurrence dose limit toxicity , define occurrence Grade IV GVHD SAE deem least probably definitely related investigational product . The primary efficacy endpoint phase II proportion CMV reactivation require treatment day 100 post transplant . Secondary endpoint technical feasibility MSVT manufacture , pattern virus reactivation PCR , clinical disease EBV , Ad , BK , day 100 non-relapse mortality .</brief_summary>
	<brief_title>Phase I/II Trial Early Infusion Rapidly-generated Multivirus Specific T Cells ( MVST ) Prevent Post Transplant Viral Infections</brief_title>
	<detailed_description>Allogeneic hematopoetic stem cell transplantation ( SCT ) frequently complicate life threaten viral reactivation . Conventional antiviral therapy suboptimal cytomegalovirus ( CMV ) , adenovirus ( AdV ) Epstein-Barr virus ( EBV ) nonexistent BK virus ( BKV ) . An alternative approach prevent viral reactivation infuse virus-specific cytotoxic T cell ( CTL ) prepare donor early SCT . Such multivirus-specific CTL cell ( MVST ) successfully use number center prevent treat CMV , Ad EBV . Activity BKV-reactive cell study . Multi virus-specific T cell ( MVST ) donor lymphocytes highly enriched viral antigen expand vitro infusion transplant recipient . Viral reactivation particular problem inT cell deplete SCT . Median time CMV reactivation estimate 28 day post T-depleted transplant , infusion MVST within immediate post-SCT period previously study . This protocol first plan series cellular therapy layer exist T lymphocyte deplete transplant platform protocol 13-H-0144 . The aim study determine safety efficacy early infusion MVSTr cell direct four common virus cause complication T-depleted SCT . GMP-grade allogeneic MVSTr stem cell donor generate use peripheral blood mononuclear cell ( PBMCs ) pulse overlap peptide library immunodominant antigen CMV , EBV , Ad , BKV expand IL-7 IL-15 follow IL-2 14 day . A fraction routine donor leukapheresis lymphocyte obtain prior stem cell mobilization use generate MVST cell . MVST pass release criterion cryopreserved ready infusion post SCT . Eligible subject NHLBI protocol 13-H-0144 receive single early infusion MVSTr day +7 post transplant range 0-14 day ) post SCT . Phase I safety monitor continue 6 week . Viral reactivation ( CMV , EBV , Ad , BK ) monitor PCR serial blood sampling . The antiviral prophylaxis give acyclovir prevent herpes simplex varicella zoster reactivation . Subjects rise PCR exceed threshold treatment , clinically overt viral disease receive conventional antiviral treatment . Patients develop acute GVHD receive standard treatment systemic steroid . These patient eligible reinfusion MVST steroid taper . The clinical trial design single institution , open label , non-randomized Phase I/II trial MVST transplant recipient , design 2-cohort dose escalation Phase I follow 20 subject extension Phase II maximum tolerate dose cell . Safety monitor continuously period 6 week post T cell transfer . The primary safety endpoint occurrence dose limit toxicity ( DLT ) , define occurrence Grade IV GVHD , Grade III cytokine release syndrome ( CRS ) , Grade III autoimmunity SAE deem least probably definitely related investigational product . The primary efficacy endpoint phase II proportion CMV reactivation require treatment day 100 post transplant . Secondary endpoint technical feasibility MSVT manufacture , pattern virus reactivation PCR , clinical disease EBV , Ad , BK , day 100 non-relapse mortality , well rate viral disease , chronic GVHD graft failure one year post SCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>INCLUSION CRITERIA : Recipient Ages 1875 year inclusive ( Will seek plan amendment Phase I result safety efficacy available justify extend trial pediatric recipient Phase II ) . Patients hematologic malignancy sign consent NHLBI transplant protocol 13H0144 . Susceptible CMV reactivation post transplant ( either donor recipient need seropositive CMV time prior transplant ) . Ability comprehend investigational nature study provide inform consent . EXCLUSION CRITERIA : Recipient Positive pregnancy test woman childbearing age . DLCO adjust Hb ventilation &lt; 50 % predict prior SCT Left ventricular ejection fraction &lt; 40 % ( evaluated ECHO ) &lt; 30 % ( evaluated MUGA ) prior SCT AST/SGOT &gt; 10 time ULN ( &gt; grade 3 , CTCAE ) Bilirubin &gt; 5 time ULN ( &gt; grade 3 , CTCAE ) Estimated GFR &lt; 15 mL/min Receiving Ganciclovir , Foscarnet Cidofovir Receiving corticosteroid dose equivalent 0.5 mg/kg/day methylprednisolone Evidence active autoimmune process</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 15, 2017</verification_date>
	<keyword>BK Virus</keyword>
	<keyword>Cytotoxic T Cells</keyword>
	<keyword>EBV</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>CMV</keyword>
</DOC>